Remy Sukhija
2021
Compensation breakdown
| Non-Equity Incentive Plan | $248,436 |
|---|---|
| Option Awards | $2,048,400 |
| Salary | $461,250 |
| Other | $10,381 |
| Total | $2,768,467 |
Sukhija received $2M in option awards, accounting for 74% of the total pay in 2021.
Sukhija also received $248.4K in non-equity incentive plan, $461.3K in salary and $10.4K in other compensation.
Rankings
In 2021, Remy Sukhija's compensation ranked 4,750th out of 12,406 executives tracked by ExecPay. In other words, Sukhija earned more than 61.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,750 out of 12,406 | 62nd |
Division Manufacturing | 1,974 out of 5,492 | 64th |
Major group Chemicals And Allied Products | 830 out of 2,368 | 65th |
Industry group Drugs | 743 out of 2,089 | 64th |
Industry Pharmaceutical Preparations | 531 out of 1,536 | 65th |
Pay ratio
| Remy Sukhija's Pay | $2,768,467 |
|---|---|
| Median Employee's Pay | $459,419 |
| Pay Ratio | 6to 1 |
In 2021, the annual total compensation of Remy Sukhija was $2,768,467.
The annual total compensation of the median employee at Synta Pharmaceuticals was $459,419.
The ratio of Remy Sukhija's pay to the pay of median employee was therefore 6 to one.
Sukhija's colleagues
We found five more compensation records of executives who worked with Remy Sukhija at Synta Pharmaceuticals in 2021.
2021
Alex Howarth
Synta Pharmaceuticals
Chief Financial Officer
2021
Paul Friedman
Synta Pharmaceuticals
Chief Executive Officer
2021
Rebecca Taub
Synta Pharmaceuticals
Chief Medical Officer
2021
Marc Schneebaum
Synta Pharmaceuticals
Chief Financial Officer
2021
Brian Lynch
Synta Pharmaceuticals